We are live on ! Find out more
VRPX

Virpax Pharmaceuticals, Inc. Common Stock
VRPX

Delisted

VRPX was delisted on the 3rd of April, 2025.

Back to rankings

15 hedge funds and large institutions have $121K invested in Virpax Pharmaceuticals, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

50% more funds holding

Funds holding: 10 → 15 (+5)

76% less capital invested

Capital invested by funds: $493K → $121K (-$373K)

Holders
15
Holders Change
+5
Holders Change %
+50%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SSWM
Sheets Smith Wealth Management
North Carolina
+$30K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$10.6K
3
TSS
Two Sigma Securities
New York
+$7.04K
4
UBS Group
UBS Group
Switzerland
+$3.89K
5
JP Morgan Chase
JP Morgan Chase
New York
+$2.55K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$234K
2
Renaissance Technologies
Renaissance Technologies
New York
-$24.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
PNC Financial Services Group
1
PNC Financial Services Group
Pennsylvania
$32.3K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$21.2K +$599 +4 +2%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$20.2K – – –
SSWM
4
Sheets Smith Wealth Management
North Carolina
$16K +$30K +200 New
Renaissance Technologies
5
Renaissance Technologies
New York
$10K -$24.3K -162 -57%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$5.59K +$10.6K +71 New
Northern Trust
7
Northern Trust
Illinois
$4.87K – – –
TSS
8
Two Sigma Securities
New York
$3.74K +$7.04K +47 New
UBS Group
9
UBS Group
Switzerland
$2.12K +$3.89K +26 New
TRCT
10
Tower Research Capital (TRC)
New York
$2.02K – – –
JP Morgan Chase
11
JP Morgan Chase
New York
$1.37K +$2.55K +17 New
Osaic Holdings
12
Osaic Holdings
Arizona
$768 +$1.2K +8 +400%
SRCM
13
Signature Resources Capital Management
California
$160 +$300 +2 New
BlackRock
14
BlackRock
New York
$149 – – –
Morgan Stanley
15
Morgan Stanley
New York
$96 – – –
Wells Fargo
16
Wells Fargo
California
$21 – – –
PA
17
Parallel Advisors
California
$5 – – –
SM
18
Sabby Management
Florida
– -$234K -1,171 Closed

VRPX Hedge Fund Activity: Q4 2023 in Review

15 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q4 2023, worth a combined $121K — down 76% from $493K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new VRPX positions and 1 closed out — a net gain of 5 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Sheets Smith Wealth Management, opening a new position worth an estimated $30K. The largest seller was Sabby Management, exiting entirely with an estimated $234K sold.

  • 15 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q4 2023, up from 10 in Q3 2023.
  • Funds reported $121K of Virpax Pharmaceuticals, Inc. Common Stock stock for Q4 2023, down 76% quarter-over-quarter.
  • 6 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q4 2023 and 1 closed out, a net change of +5 holders.
  • The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q4 2023 was Sheets Smith Wealth Management, an estimated $30K added.
  • The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q4 2023 was Sabby Management, an estimated $234K sold.

Based on aggregated 13F filings for Q4 2023.